ExodusPoint Capital Management’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
ExodusPoint Capital Management's MLYS Position: Q3 2026 in Review
ExodusPoint Capital Management sold out of Mineralys Therapeutics (MLYS) in Q3 2026, closing a stake of 101,052 shares — an estimated $2.73M sold.
ExodusPoint Capital Management first reported a position in MLYS in Q1 2023 and held it in 9 quarters. The position peaked at $3.3M in Q2 2023. 184 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- ExodusPoint Capital Management reported no remaining Mineralys Therapeutics position as of Q3 2026 after selling out during the quarter.
- ExodusPoint Capital Management sold 101,052 Mineralys Therapeutics shares in Q3 2026, an estimated $2.73M.
- ExodusPoint Capital Management first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 9 quarters.
- ExodusPoint Capital Management's Mineralys Therapeutics position peaked at $3.3M in Q2 2023.
- 184 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.